Nitrogen Containing Patents (Class 514/459)
-
Patent number: 8552042Abstract: The invention relates to the use of an antimycotic agent and an epithelial cell or endothelial cell adhesion inhibitor for producing a combination drug for the topical treatment of Candida mycoses selected from vulvovaginal candidiasis, oropharyngeal candidiasis (oral thrush), diaper dermatitis (diaper thrush) and intertriginous (Candida) eczema.Type: GrantFiled: May 10, 2007Date of Patent: October 8, 2013Inventors: Christian Noe, Marion Noe
-
Publication number: 20130251790Abstract: The present invention provides a pharmaceutical composition comprising a low dose of zanamivir and a process for preparing the pharmaceutical composition comprising a low dose of zanamivir. The pharmaceutical composition comprising a low dose zanamivir may be used in the treatment and/or prophylaxis of influenza. The present invention also provides a method of treatment and/or prophylaxis of influenza which comprises administering a dry powder inhaler composition comprising a low dose zanamivir. The pharmaceutical composition of the present invention comprises zanamivir and one or more pharmaceutically acceptable excipients, wherein the total daily dose of the zanamivir is less than 10 mg, preferably for administration at least once a day, and preferably wherein the composition delivers from 3 mg to 8 mg of zanamivir per administered dose.Type: ApplicationFiled: September 26, 2011Publication date: September 26, 2013Applicant: CIPLA LIMITEDInventors: Geena Malhotra, Shrinivas Madhukar Purandare
-
Publication number: 20130245101Abstract: Therapeutic conjugates containing a statin or a modified statin (collectively “statin”) linked to a therapeutic agent (also referred to as a drug herein) are targeted to the liver by the statin or modified statin and thereby deliver the therapeutic agent to liver cellsType: ApplicationFiled: April 24, 2013Publication date: September 19, 2013Inventors: Gregory L. Verdine, Yoshihiko Norimine, Lourdes Gude-Rodriguez
-
Publication number: 20130237536Abstract: Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.Type: ApplicationFiled: April 26, 2013Publication date: September 12, 2013Applicant: The Cleveland Clinic FoundationInventors: Mohamed Naguib Attala, Philippe Diaz
-
Publication number: 20130231376Abstract: Disclosed are methods of treating and/or preventing infections in mammals caused by microorganisms, by administering to a mammal a therapeutically effective amount of at least one defensin-like molecule, e.g., in a composition that includes such molecule. Also disclosed are the use of such defensin-like molecules for treating and/or preventing infections in mammals; and kits that may include such molecules, or compositions that include such molecules, as well as instructions for using such molecules to treat a mammal.Type: ApplicationFiled: November 4, 2011Publication date: September 5, 2013Applicant: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Erik De Leeuw, Alexander D. MacKerell, Jr.
-
Patent number: 8524909Abstract: The present invention relates to a compound of formula I wherein R1/R2 are independently from each other hydrogen, (CR2)o-cycloalkyl, optionally substituted by lower alkyl or hydroxy, or are lower alkyl or heterocycloalkyl, and o is 0 or 1; and R may be the same or different and is hydrogen or lower alkyl; or R1 and R2 may form together with the N atom to which they are attached a heterocycloalkyl group, selected from the group consisting of pyrrolidinyl, piperidinyl, 3-aza-bicyclo[3.1.0]hex-3-yl or 2-aza-bicyclo[3.1.Type: GrantFiled: January 21, 2011Date of Patent: September 3, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Sabine Kolczewski, Emmanuel Pinard
-
Patent number: 8518915Abstract: The invention relates to pharmacology and medicine, in particular to a class of mitochondrially-addressed compounds which can be used in the pharmaceutical compositions of medicinal agents (preparations) for preventing and treating cardiovascular diseases and diseases and pathological conditions caused by disturbed blood circulation or oxygen supply to tissues and organs.Type: GrantFiled: June 29, 2007Date of Patent: August 27, 2013Assignee: Mitotech SAInventors: Maxim Vladimirovich Skulachev, Vladimir Petrovich Skulachev
-
Publication number: 20130217762Abstract: The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.Type: ApplicationFiled: October 5, 2012Publication date: August 22, 2013Applicant: ELI LILLY AND COMPANYInventor: Eli Lilly and Company
-
Publication number: 20130197072Abstract: Methods for manufacturing neuraminic acid compounds and synthetic intermediates of neuraminic acid compounds, including a method for manufacturing a compound represented by wherein R2 represents a C1-C4 alkyl, R3 represents a C1-C6 alkyl, R4 and R5 represent a hydrogen atom, a C1-C6 alkyl or a phenyl, or R4 and R5 together form a tetramethylene, a pentamethylene or an oxo, and Ac represents an acetyl, comprising reacting a compound represented by wherein R2 represents a C1-C4 alkyl, R3 represents a C1-C6 alkyl, R4 and R5 represent a hydrogen atom, a C1-C6 alkyl or a phenyl, or R4 and R5 together form a tetramethylene, a pentamethylene or an oxo, with trimethylsilyl azide in the presence of a Lewis acid.Type: ApplicationFiled: March 12, 2013Publication date: August 1, 2013Applicant: DAIICHI SANKYO CO., LTD.Inventor: DAIICHI SANKYO CO., LTD.
-
Publication number: 20130184279Abstract: Compounds of formula Ia and Ib wherein A, B, C, R1 and R14 are described herein.Type: ApplicationFiled: December 18, 2012Publication date: July 18, 2013Applicant: Bristol-Myers Squibb CompanyInventor: Bristol-Myers Squibb Company
-
Publication number: 20130178446Abstract: The present invention is directed to the topical application of the malonamide ACAT inhibitors described by Formula I. Other aspects of the invention are directed to topical formulations of these diamides, their use to treat sebaceous gland disorders and their use to alleviate oily skin.Type: ApplicationFiled: March 4, 2013Publication date: July 11, 2013Applicant: Medicis Pharmaceutical CorporationInventors: Catherine R. Kostlan, Raj Neil Raheja, Meera Tugnait, Kimberly Wade
-
Publication number: 20130150390Abstract: A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.Type: ApplicationFiled: December 12, 2012Publication date: June 13, 2013Inventors: Mie Kaino, Hiroyuki Meguro
-
Patent number: 8440832Abstract: Heterocyclic compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.Type: GrantFiled: July 14, 2008Date of Patent: May 14, 2013Assignee: Board of Regents, The University of Texas SystemInventors: Mohamed Naguib Attala, Philippe Diaz
-
Publication number: 20130109718Abstract: This invention relates to novel 1-cycloalkyl- or 1-heterocyclyl-hydroxyimino-3-phenyl-propanes of the formula wherein R1 to R7 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and may therefore be useful as medicaments for the treatment of diseases such as type II diabetes.Type: ApplicationFiled: October 24, 2012Publication date: May 2, 2013Applicant: Hoffmann-La Roche Inc.Inventor: Hoffmann-La Roche Inc.
-
Publication number: 20130101667Abstract: The present application provides novel compounds and methods for preparing and using these compounds. These compounds are useful in treating pain, itch, overactive bladder and/or interstitial cystitis in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.Type: ApplicationFiled: October 24, 2012Publication date: April 25, 2013Applicant: ENDO PHARMACEUTICALS, INC.Inventor: Endo Pharmaceuticals, Inc.
-
Publication number: 20130045951Abstract: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.Type: ApplicationFiled: October 18, 2012Publication date: February 21, 2013Applicant: CARDIOXYL PHARMACEUTICALS, INC.Inventor: CARDIOXYL PHARMACEUTICALS, INC.
-
Publication number: 20130039885Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.Type: ApplicationFiled: June 19, 2012Publication date: February 14, 2013Applicant: NEW YORK UNIVERSITYInventors: Victor J. TORRES, Derya UNUTMAZ, Francis ALONZO, III
-
Publication number: 20130030048Abstract: The present invention relates to the novel use of a composition comprising a compound of the formula I: wherein R is C2H5 or C2H3, or a pharmaceutically acceptable salt thereof, for inducing multiple nuclear divisions of cells; inducing tissues, blood vessels or organs to regenerate after the multiple nuclear divisions; or inducing stem cells to differentiate into immunocytes after the multiple nuclear divisions.Type: ApplicationFiled: October 1, 2012Publication date: January 31, 2013Inventor: Gee-Hwoon LEE
-
Publication number: 20130023585Abstract: Disclosed are neuraminidase inhibitor compounds and pharmaceutical compositions with improved bioavailability and/or improved efficacy and methods of treating influenza using the compounds and pharmaceuticals compositions.Type: ApplicationFiled: April 4, 2011Publication date: January 24, 2013Applicant: TSRL, INC.Inventors: John Hilfinger, Wei Shen
-
Publication number: 20130018077Abstract: Provided are alkynyl phenyl derivative compounds, pharmaceutical compositions thereof, and methods of treating ophthalmic diseases and disorders, such as age-related macular degeneration and Stargardt's Disease, using said compounds and compositions.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Applicant: Acucela Inc.Inventors: Ian Leslie Scott, Vladmir Aleksandrovich Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Jennifer Gage, Feng Hong
-
Patent number: 8354095Abstract: The biodegradable drug delivery systems described here are formulated for implantation into the nail unit and its surrounding tissues for the treatment of various nail unit conditions. The systems include greater than 30% by weight of the active agent, and may be formulated as solutions, solids, semisolids, microparticles, or crystals. Methods related to the implantation and use of the biodegradable drug delivery systems for treating nail unit conditions are also described.Type: GrantFiled: February 11, 2008Date of Patent: January 15, 2013Assignee: Hallux, Inc.Inventors: Frank M. Kochinke, Corinne Bright
-
Publication number: 20130012502Abstract: Pharmaceutical or veterinary compositions to prevent or treat viral infections, in particular to prevent or treat influenza A, B and C virus infections.Type: ApplicationFiled: December 7, 2010Publication date: January 10, 2013Applicants: HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Manuel Rosa-Calatrava, Jean-Jacques Diaz, Julien Textoris, Laurence Josset
-
Publication number: 20130005799Abstract: This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogues for the treatment of a tumor expressing a ?2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a ?2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analogue or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.Type: ApplicationFiled: March 10, 2011Publication date: January 3, 2013Inventors: Irving W. Wainer, Michel Bernier, Lawrence Robert Toll, Lucita Arenas Jimenez
-
Publication number: 20130004577Abstract: A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (DMDO) group. The present invention provides a coated tablet characterized in that an uncoated tablet containing a drug having a guanidino group has been coated with a polyvinyl alcohol for film coating which comprises polyvinyl alcohol, acrylic acid, and methyl methacrylate.Type: ApplicationFiled: September 7, 2012Publication date: January 3, 2013Applicant: NIPPON SHINYAKUInventors: Hironobu KATO, Hirokazu SAKAMOTO
-
Publication number: 20120329775Abstract: The present invention provides compounds of formula (I) in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: June 4, 2012Publication date: December 27, 2012Inventors: Rhonan Ford, Andrew Mather, Antonio Mete, Ian Millichip
-
Patent number: 8338410Abstract: This invention relates to the use of at least one compound of the following formula (I): or its pharmaceutically acceptable salts, for the preparation of a medicinal compound having neuroprotective activity intended to prevent or treat neurone deteriorations.Type: GrantFiled: July 18, 2006Date of Patent: December 25, 2012Assignee: BiocodexInventors: Marc Verleye, Marie-Emmanuelle Le Guern, Philippe Girard, Jean-Marie Gillardin, Laurence Berthon-Cedille, Bernard Hublot
-
Publication number: 20120316173Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.Type: ApplicationFiled: January 11, 2011Publication date: December 13, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Alessandra Bartolozzi, Angela Berry, Doris Riether, Monika Ermann, James Edward Jenkins, Innocent Mushi
-
Publication number: 20120295923Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.Type: ApplicationFiled: January 19, 2011Publication date: November 22, 2012Inventors: Christopher William Am Ende, Benjamin Adam Fish, Douglas Scott Johnson, Ricardo Lira, Christopher John O'Donnell, Martin Youngjin Pettersson, Corey Michael Stiff
-
Publication number: 20120295886Abstract: The present disclosure provides compounds having affinity for the M2 proton channel, useful for the treatment of viral infections such as influenza, which are of the Formula (I): wherein R1, R2, and Y are as defined herein. Methods of preparing the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds in the treatment of viral infections such as influenza are also provided.Type: ApplicationFiled: May 18, 2012Publication date: November 22, 2012Applicant: INFLUMEDIX, INC.Inventors: Jizhou Wang, Xiaodong Fan, Lidia Cristian
-
Publication number: 20120269722Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: ApplicationFiled: April 20, 2012Publication date: October 25, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Simon LEPPARD, Pedro GARCIA, Brenda HALL, Maria Victoria Fajardo GONZALEZ
-
Publication number: 20120269771Abstract: The present invention discloses a new class of compounds that exhibit an inhibitory effect on influenza virus type A and B, which may or may not be resistant to other drugs, as well as on other types of viruses, such as flavivirus but also on protozoa and other micro-organisms, their preparation methods, pharmaceutical formulations containing them and their use as medicinal products for the treatment of various conditions caused by particular microorganisms, including viruses, bacteria and protozoa, which affect animal and human health.Type: ApplicationFiled: November 25, 2010Publication date: October 25, 2012Inventors: Paolo Alberto Veronesi, Pablo E.A. Rodriguez, Anna Maria Veronesi, Emanuela Peschechera
-
Publication number: 20120253191Abstract: The application relates to a nanovesicle comprising a bilayer of at least 15 mol % porphyrin-phospholipid conjugate, wherein the conjugate comprises a porphyrin, porphyrin derivative or porphyrin analog covalently attached to the phospholipid side chain. The nanovesicle can be used for photothermal therapy, photoacoustic imaging, and fluorescence imaging. The application also discloses a method of preparing the said nanovesicle.Type: ApplicationFiled: October 5, 2010Publication date: October 4, 2012Applicant: UNIVERSITY HEALTH NETWORKInventors: Gang Zheng, Jonathan F. Lovell
-
Publication number: 20120225062Abstract: The present invention provides compounds of Formula I: and related compounds as further described herein, and pharmaceutical compositions comprising these compounds. The invention further provides methods to use these compounds and compositions for treating disorders associated with undesired levels of Pim kinase activity, including cancers and autoimmune disorders.Type: ApplicationFiled: March 2, 2012Publication date: September 6, 2012Inventors: Matthew Burger, Gisele Nishiguchi, Timothy D. Machajewski, Alice Rico, Robert Lowell Simmons, Aaron R. Smith, Victoriano Tamez, JR., Huw Tanner, Lifeng Wan
-
Publication number: 20120220590Abstract: Compounds of formula (I) and pharmaceutical compositions containing them are described. The use of the compounds and compositions are also described.Type: ApplicationFiled: July 30, 2010Publication date: August 30, 2012Inventors: Pravin S. Thombare, Amitgiri Goswami, Edouard Zamaratski, Tomas Hansson, Thomas Norin
-
Publication number: 20120214852Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: November 8, 2011Publication date: August 23, 2012Applicant: Acucela Inc.Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
-
Publication number: 20120213844Abstract: Short oligopeptides are provide which are capable of binding to the epidermal growth factor receptor on the surface of human tumor cells. Methods for using the peptides as targeting moieties in more complex compositions, such as conjugates of cytoxins, and/or structures, such as liposomal structures, for the purposes of drug delivery are also provided.Type: ApplicationFiled: December 20, 2007Publication date: August 23, 2012Inventors: Ken Shi Kun Huang, Weiming Zhang, Guoyang Zhang, Francois Nicol, Anthony Huang
-
Publication number: 20120190710Abstract: The present invention provides bicyclo-heptan-2-amines that selectively bind to the sigma-2 receptor and are useful in the treatment of diseases related to the sigma-2 receptor, for example, cancer and neurological disorders.Type: ApplicationFiled: January 20, 2012Publication date: July 26, 2012Applicant: Adeboye AdejareInventors: Adeboye Adejare, Zeynep Ates-Alagoz, Boyenoh Gaye
-
Publication number: 20120184520Abstract: [Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.Type: ApplicationFiled: September 15, 2010Publication date: July 19, 2012Applicant: Astellas Pharma Inc.Inventors: Kousei Yoshihara, Daisuke Suzuki, Susumu Yamaki, Yuji Koga, Norio Seki, Jiro Fujiyasu, Masahiro Neya
-
Publication number: 20120184606Abstract: Compounds having a structure of Formula I and compositions comprising these compounds are provided. Uses of such compounds and compositions are provided for treatment or prophylaxis of viral infection. In particular, compounds and compositions may be for use in the treatment or prophylaxis of viral influenza.Type: ApplicationFiled: January 19, 2012Publication date: July 19, 2012Inventors: Stephen Withers, Andrew Graham Watts, Jin Hyo Kim, Tom Wennekes
-
Publication number: 20120178802Abstract: Compounds of structural formula (I) useful for the treatment or prophylaxis of viral infection, particularly viral influenza are provided Pharmaceutical preparations thereof and methods for their preparation are also described. The therapeutic effect is achieved via inhibition of viral neuraminidases, also known as viral sialidases. These neuraminidases are classified under the GH34 family of viral enzymes.Type: ApplicationFiled: July 15, 2010Publication date: July 12, 2012Inventors: Stephen Withers, Andrew Graham Watts, Jin Hyo Kim, Tom Wennekes
-
Publication number: 20120157519Abstract: Tellurium-containing compounds identified for use in a method of treating, or prophylaxis against, a viral infection caused by an influenza virus, uses thereof and pharmaceutical kits and pharmaceutical corn positions comprising the same, are disclosed. The tellurium-containing compounds disclosed herein are suitable for co-administration with an antiviral agent.Type: ApplicationFiled: June 16, 2010Publication date: June 21, 2012Applicant: Biomas Ltd.Inventors: Benjamin Sredni, Michael Albeck
-
Publication number: 20120148595Abstract: The present invention relates to GABA-linked anthracycline-lipid conjugates and to methods of using the conjugates to treat cancer. Methods for making the GABA-linked anthracycline lipid conjugates are also provided.Type: ApplicationFiled: March 11, 2010Publication date: June 14, 2012Applicant: Luitpold Pharmaceuticals, Inc.Inventors: Charles S. Swindell, Glenn G. Fegley, Hema M. Sundar, Richard Lawrence
-
Patent number: 8183273Abstract: The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R1 is a 5- to 6-membered ring group which may be substituted; X1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2 is a bivalent group of 1 to 4 atoms; Z1 is a bivalent cyclic ring group or the like; Z2 is a bond or the like; and R2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.Type: GrantFiled: October 25, 2007Date of Patent: May 22, 2012Assignee: Tobira Therapeutics, Inc.Inventors: Mitsuru Shiraishi, Masanori Baba, Katsuji Aikawa, Naoyuki Kanzaki, Masaki Seto, Yuji Iizawa
-
Publication number: 20120122938Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: November 8, 2011Publication date: May 17, 2012Applicant: Acucela Inc.Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
-
Patent number: 8178658Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.Type: GrantFiled: February 11, 2009Date of Patent: May 15, 2012Assignee: Dow AgroSciences, LLCInventors: Gary D. Crouse, Thomas C. Sparks, CaSandra L. McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
-
Publication number: 20120115862Abstract: The present invention relates to compounds of the formula I wherein R1, R2, R3, R4, X and Y have the meanings given in the description. The compounds have an action which is immunomodulating and inhibits or regulates the release of IL-1? and/or TNF-?. They can therefore be used for treatment of diseases connected with a disturbance in the immune system.Type: ApplicationFiled: October 9, 2009Publication date: May 10, 2012Inventors: Stefan Laufer, Wolfgang Albrecht
-
Publication number: 20120114661Abstract: Methods of identifying infectious disease infection prior to presentation of symptoms, assays for identifying genomic markers of infectious disease, and methods for diagnosing the underlying etiology of infectious disease.Type: ApplicationFiled: May 26, 2010Publication date: May 10, 2012Inventors: Geoffrey S. Ginsburg, Joseph Lucas, Christopher W. Woods, Lawrence Carin, Aimee K. Zaas, Alfred Hero
-
Publication number: 20120101091Abstract: The present application provides compounds of formula I wherein X, Y, R2, n, R5 and R6 are defined herein, useful as inhibitors of the hepatitis C virus NS5B polymerase The present application also provides pharmaceutical compositions containing said compounds, methods of using said compounds as pharmaceuticals alone or with other antiviral agent in the treatment of a hepatitis C viral infection in a mammal having or at risk of having the infection.Type: ApplicationFiled: October 1, 2009Publication date: April 26, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Pierre Beaulieu, Pierre Bonneau, René Coulombe, Pasquale Forgione, James Gillard, Araz Jakalian, Jean Rancourt
-
Publication number: 20120087928Abstract: The invention provides compositions and methods of predicting a subject's risk of developing age-related macular degeneration (AMD) and methods of treating, delaying, or preventing the development and progression of AMD.Type: ApplicationFiled: October 28, 2011Publication date: April 12, 2012Inventor: Kameran Lashkari
-
Publication number: 20120077876Abstract: This invention relates to a prodrug comprising a partial structure having the general formula (I) or (II), where R1 and R2 are hydrogen, alkyl, or aryl radicals.Type: ApplicationFiled: January 8, 2010Publication date: March 29, 2012Applicant: Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. KGInventors: Bernd Clement, Dennis Schade